HRPK20040255B3 - Processes for preparing calcium salt forms of statins - Google Patents

Processes for preparing calcium salt forms of statins

Info

Publication number
HRPK20040255B3
HRPK20040255B3 HR20040255A HRP20040255A HRPK20040255B3 HR PK20040255 B3 HRPK20040255 B3 HR PK20040255B3 HR 20040255 A HR20040255 A HR 20040255A HR P20040255 A HRP20040255 A HR P20040255A HR PK20040255 B3 HRPK20040255 B3 HR PK20040255B3
Authority
HR
Croatia
Prior art keywords
calcium salt
statins
processes
salt forms
preparing calcium
Prior art date
Application number
HR20040255A
Other languages
English (en)
Croatian (hr)
Inventor
Lidor-Hadas Rami
Lifshitz-Liron Revital
Niddam-Hildesheim Valerie
Original Assignee
Teva Pharmaceutical Industries Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/037,412 external-priority patent/US6528661B2/en
Application filed by Teva Pharmaceutical Industries Ltd. filed Critical Teva Pharmaceutical Industries Ltd.
Publication of HRP20040255A2 publication Critical patent/HRP20040255A2/hr
Publication of HRPK20040255B3 publication Critical patent/HRPK20040255B3/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Indole Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Pyrrole Compounds (AREA)
HR20040255A 2001-08-16 2004-03-15 Processes for preparing calcium salt forms of statins HRPK20040255B3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31281201P 2001-08-16 2001-08-16
US10/037,412 US6528661B2 (en) 2000-11-16 2001-10-24 Hydrolysis of [R(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino) carbonyl]-1H-pyrrole-1-heptanoic acid esters with calcium hydroxide
PCT/US2002/026012 WO2003016317A1 (en) 2001-08-16 2002-08-16 Processes for preparing calcium salt forms of statins

Publications (2)

Publication Number Publication Date
HRP20040255A2 HRP20040255A2 (en) 2004-08-31
HRPK20040255B3 true HRPK20040255B3 (en) 2006-02-28

Family

ID=26714105

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20040255A HRPK20040255B3 (en) 2001-08-16 2004-03-15 Processes for preparing calcium salt forms of statins

Country Status (17)

Country Link
EP (1) EP1425287A4 (no)
JP (2) JP4188826B2 (no)
CN (1) CN100430405C (no)
AU (1) AU2002324715B2 (no)
CA (1) CA2450820C (no)
CZ (1) CZ2004337A3 (no)
HR (1) HRPK20040255B3 (no)
HU (1) HUP0500616A3 (no)
IL (2) IL160077A0 (no)
IS (1) IS7148A (no)
MX (1) MXPA04001451A (no)
NO (1) NO20041082L (no)
NZ (1) NZ529913A (no)
PL (1) PL370407A1 (no)
SK (1) SK1402004A3 (no)
TR (1) TR200302281T2 (no)
WO (1) WO2003016317A1 (no)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
ATE410413T1 (de) * 2000-11-16 2008-10-15 Teva Pharma Hydrolyse von är(r*,r*)ü-2-(4-fluorphenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4- ä(phenylamino)carbonylü-1h-pyrrol- heptansäureestern mit calciumhydroxid
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US7501450B2 (en) 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
WO2002057229A1 (en) 2001-01-19 2002-07-25 Biocon India Limited FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
US7361772B2 (en) 2001-08-16 2008-04-22 Biocon Limited Process for the production of atorvastatin calcium
CA2412012C (en) 2001-11-20 2011-08-02 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Resorbable extracellular matrix containing collagen i and collagen ii for reconstruction of cartilage
US7230120B2 (en) 2002-03-18 2007-06-12 Biocon Amorphous HMG-CoA reductase inhibitors of desired particle size
WO2003097614A2 (en) * 2002-05-21 2003-11-27 Ranbaxy Laboratories Limited Process for the preparation of rosuvastatin
US7179942B2 (en) 2002-07-05 2007-02-20 Bicon Limited Halo-substituted active methylene compounds
GB0218781D0 (en) * 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
CN102285916B (zh) * 2003-02-12 2015-02-25 日产化学工业株式会社 匹伐他汀钙的晶形
DK1631533T3 (da) 2003-04-22 2009-06-02 Biocon Ltd Hidtil ukendt fremgangsmåde til stereoselektiv reduktion af beta-ketoestre
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
KR101113163B1 (ko) 2003-07-25 2012-02-17 브래드포드 파마 리미티드 스타틴, 특히 아토르바스타틴의 제조에 유용한 중간체화합물 및 그 제조방법
AU2003269477A1 (en) * 2003-08-26 2005-03-10 Biocon Limited Novel process for preparation of 7-(3-(4-fluorophenyl)-1-(1-methylethyl)-1h-indol-2-yl)-3, 5-dihydroxy-6-heptenoic acid sodium salt
CA2537271A1 (en) * 2003-08-28 2005-03-17 Teva Pharmaceutical Industries, Ltd. Process for preparation of rosuvastatin calcium
EP1816126A1 (en) * 2003-08-28 2007-08-08 Teva Pharmaceutical Industries Limited Process for preparation of rosuvastatin calcium
UY28501A1 (es) 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
AU2003272080A1 (en) 2003-09-18 2005-04-06 Biocon Limited Novel process for the preparation of tert-butyl 6-cyano-5-hydroxy-3-oxohexanoate
US20070191318A1 (en) * 2003-10-22 2007-08-16 Yatendra Kumar Process for the preparation of amorphous rosuvastatin calcium
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
WO2005051921A1 (en) 2003-11-24 2005-06-09 Teva Pharmaceutical Industries Ltd. Crystalline ammonium salts of rosuvastatin
MY147202A (en) * 2003-11-26 2012-11-14 Novartis Ag Compositions comprising organic compounds
ATE507209T1 (de) 2003-12-02 2011-05-15 Teva Pharma Referenzstandard zur charakterisierung von rosuvastatin
TWI328006B (en) * 2003-12-26 2010-08-01 Nissan Chemical Ind Ltd Crystal form of quinoline compound and process for its production
JP2007517028A (ja) * 2003-12-29 2007-06-28 レツク・フアーマシユーテイカルズ・デー・デー 非晶質の（４ｒ−シス）−６−［２−［３−フェニル−４−（フェニルカルバモイル）−２−（４−フルオロフェニル）−５−（１−メチルエチル）−ピロール−１−イル］−エチル］−２，２−ジメチル−［１，３］−ジオキサン−４−イル−酢酸を調製する方法
CZ200486A3 (cs) * 2004-01-16 2005-08-17 Zentiva, A.S. Způsob výroby hemivápenaté soli (E)-7-[4-(4-fluorfenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxy-6-heptenové kyseliny
WO2005077917A1 (en) * 2004-01-19 2005-08-25 Ranbaxy Laboratories Limited Amorphous salts of rosuvastatin
SI21745A (sl) * 2004-04-09 2005-10-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Polimorfi derivata 1-pirol-1-heptanojske kisline, intermediata za pripravo atorvastatina
JP2007508379A (ja) 2004-07-13 2007-04-05 テバ ファーマシューティカル インダストリーズ リミティド Ｔｅｍｐｏ媒介型酸化段階を包含するロスバスタチンの調製方法
AU2005271413A1 (en) 2004-08-06 2006-02-16 Transform Pharmaceuticals, Inc. Novel statin pharmaceutical compositions and related methods of treatment
MX2007010138A (es) 2005-02-22 2007-09-27 Teva Pharma Preparacion de rosuvastatina.
CZ299215B6 (cs) * 2005-06-29 2008-05-21 Zentiva, A. S. Zpusob výroby hemivápenaté soli (E)-7-[4-(4-fluorofenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl] (3R,5S)-3,5-dihydroxy-6-heptenovékyseliny
MX2008001597A (es) * 2005-08-04 2008-04-04 Transform Pharmaceuticals Inc Formulaciones novedosas que comprenden fenofibrato y una estatina y metodos relacionados de tratamiento.
EP1805148A2 (en) 2005-08-16 2007-07-11 Teva Pharmaceutical Industries Ltd. Crystalline rosuvastatin intermediate
CN100371709C (zh) * 2005-12-12 2008-02-27 重庆医药工业研究院有限责任公司 一种用液相色谱法分离测定匹伐他汀及其光学异构体的方法
US8455640B2 (en) 2006-05-03 2013-06-04 Msn Laboratories Limited Process for statins and its pharmaceutically acceptable salts thereof
EP2086945B1 (en) 2006-10-09 2016-01-06 MSN Laboratories Private Limited Novel process for the preparation of statins and their pharmaceutically acceptable salts thereof
EP2022784A1 (en) 2007-08-08 2009-02-11 LEK Pharmaceuticals D.D. Process for the preparation of methyl ester of rosuvastatin
WO2010089770A2 (en) 2009-01-19 2010-08-12 Msn Laboratories Limited Improved process for the preparation of highly pure (3r,5s)-7-[2-cyclopropyl-4-(4-fluorophenyl) quinolin-3-yl]-3,5-dihydroxy-6(e)-heptenoic acid and pharmaceutically acceptable salts thereof
WO2011086584A2 (en) 2010-01-18 2011-07-21 Msn Laboratories Limited Improved process for the preparation of amide intermediates and their use thereof
HUP1000299A2 (hu) 2010-06-08 2012-02-28 Nanoform Cardiovascular Therapeutics Ltd Nanostrukturált Atorvastatint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás elõállításukra
EP2638013A4 (en) * 2010-11-12 2014-03-26 Hetero Research Foundation NEW POLYMORPHS OF CALCIUM PIVASTATIN
HU229260B1 (en) * 2010-11-29 2013-10-28 Egis Gyogyszergyar Nyrt Process for preparation of rosuvastatin salts
CN102875504A (zh) * 2011-07-13 2013-01-16 华南理工大学 4,5,6,7-四氢普伐他汀及其盐在心血管上的用途
CN102302452B (zh) * 2011-09-14 2012-11-21 海南美大制药有限公司 匹伐他汀钙脂质体固体制剂
CN102796036B (zh) * 2012-09-12 2014-06-04 江苏阿尔法药业有限公司 一种阿托伐他汀钙的制备方法
CN103724278B (zh) * 2013-12-12 2019-03-29 江苏阿尔法药业有限公司 他汀类中间体及其衍生物的制备方法
US9695130B2 (en) 2014-02-06 2017-07-04 Api Corporation Rosuvastatin calcium and process for producing intermediate thereof
KR20160126700A (ko) 2015-04-24 2016-11-02 미래파인켐 주식회사 스타틴의 중간체, 이의 제조방법 및 이를 이용한 로수바스타틴의 제조방법
CN105111173B (zh) * 2015-06-26 2017-06-23 上海应用技术学院 他汀含氟衍生物及其用途
CN105017231B (zh) * 2015-06-26 2018-01-26 上海应用技术学院 多取代吲哚类他汀含氟修饰物及其用途
CN113620871A (zh) 2015-08-05 2021-11-09 株式会社Api 生产匹伐他汀钙的方法
CN111362856B (zh) * 2020-04-29 2023-08-18 福建海西新药创制股份有限公司 一种利用微反应装置生产阿托伐他汀钙的方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4137322A (en) * 1976-11-02 1979-01-30 Sankyo Company Limited ML-236B carboxylic acid derivatives and their use as antihyperlipemic agents
JPS5817443B2 (ja) * 1976-11-02 1983-04-07 三共株式会社 Ｍｌ−２３６ｂ金属塩を主成分とする高脂血症治療剤
US4857547A (en) * 1988-01-07 1989-08-15 Merck & Co., Inc. Novel HMG-CoA reductase inhibitors
ATE284868T1 (de) * 1995-07-17 2005-01-15 Warner Lambert Co Kristaline (r-(r*,r*))-2-(4-fluorphenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4- ((phenylamino)carbonyl)-1h-pyrrol-1- heptancarbonsäure hemi calcium sslz (atorvastatin)
US5669156A (en) * 1996-08-28 1997-09-23 Fleetwood Systems, Inc. Can end curing system with magnetic fanning and belt conveying
NZ503982A (en) * 1997-12-12 2002-03-28 Warner Lambert Co Statin-carboxyalkylether combinations useful for treating vascular disorders and diabetes mellitus
GB9903472D0 (en) * 1999-02-17 1999-04-07 Zeneca Ltd Chemical process
CA2364253A1 (en) * 1999-03-08 2000-09-14 Merck & Co., Inc. Dihydroxy open-acid and salts of hmg-co-a reductase inhibitors
ATE410413T1 (de) * 2000-11-16 2008-10-15 Teva Pharma Hydrolyse von är(r*,r*)ü-2-(4-fluorphenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4- ä(phenylamino)carbonylü-1h-pyrrol- heptansäureestern mit calciumhydroxid
AU2007205725A1 (en) * 2000-11-30 2007-08-30 Teva Pharmaceutical Industries Ltd. Novel cyrstal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
MXPA03005879A (es) * 2000-12-27 2003-09-10 Ciba Sc Holding Ag Formas cristalinas de atorvastatina.
EP1572638A4 (en) * 2001-08-31 2010-05-05 Morepen Lab Ltd IMPROVED PROCESS FOR THE PREPARATION OF AMORPHOUS CALCIUM ATORVASTATIN SALT (2: 1)

Also Published As

Publication number Publication date
CA2450820C (en) 2011-03-15
SK1402004A3 (sk) 2005-01-03
JP2005500382A (ja) 2005-01-06
CN100430405C (zh) 2008-11-05
IL160077A (en) 2007-10-31
HUP0500616A2 (hu) 2005-11-28
IS7148A (is) 2004-02-11
WO2003016317A1 (en) 2003-02-27
TR200302281T2 (tr) 2004-09-21
NO20041082L (no) 2004-03-15
CA2450820A1 (en) 2003-02-27
HUP0500616A3 (en) 2011-07-28
CN1543468A (zh) 2004-11-03
NZ529913A (en) 2005-03-24
AU2002324715B2 (en) 2009-03-12
JP4188826B2 (ja) 2008-12-03
CZ2004337A3 (cs) 2005-01-12
PL370407A1 (en) 2005-05-30
MXPA04001451A (es) 2005-02-17
HRP20040255A2 (en) 2004-08-31
EP1425287A1 (en) 2004-06-09
EP1425287A4 (en) 2005-09-07
JP2009024008A (ja) 2009-02-05
IL160077A0 (en) 2004-06-20

Similar Documents

Publication Publication Date Title
HRPK20040255B3 (en) Processes for preparing calcium salt forms of statins
IN2012DN00758A (no)
MY140390A (en) Sulfonylamino-derivatives as novel inhibitors of histone deacetylase
ID17851A (id) Persenyawaan heterosiklis, produksi dan pemakaiannya
TW200602322A (en) Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
TW200633991A (en) Chemical compounds
EP1780209A4 (en) OXIMESTER CONNECTION AND PHOTOPOLYMERIZATION INITIATOR CONTAINING SUCH A COMPOUND
MY153045A (en) Oxopyrazine derivative and herbicide
MX281941B (en) Anthranilamide compounds, process for their production and pesticides containing them
ATE222895T1 (de) Zwischenprodukte zur hertellung von oxazolidindion- und thiazolidindionderivate
PL370990A1 (en) Sulfonyl-derivatives as novel inhibitors of histone deacetylase
MXPA04008796A (es) Derivados de carbonilamino como novedosos inhibidores de desacetilasa de histona.
GEP20074198B (en) N-aryl-2-oxazolidinone-5-carboxamides and their derivates and their use as antibacterials
HRP20050361B1 (hr) Novi postupak za industrijsku sintezu tetraestera 5-[bis(karboksimetil)amino]-3-karboksimetil-4-cijano-2-tiofenkarboksilne kiseline i njihova primjena u sintezi bivalentnih soli ranelinske kiseline i njihovih hidrata
MEP10308A (en) Benzoylpyridine derivative or its salt, fungicide containing it as an active ingredient, its production process and intermediate for producing it
CA2418770A1 (en) Acylacetonitrile compound, process for preparation thereof, and miticide containing the same
DE60332350D1 (de) Disazofarbstoffe und sie enthaltende tintenstrahldrucktinten
MY122255A (en) Acrylonitrile compounds, process for their production and pesticides containing them
ME00455B (me) Novi postupak za industrijsku sintezu stroncijum ranelata i njegovih hidrata
SI1483245T1 (sl) 5-substituirani alkilaminopirazolni derivati kot pesticidi
DE60228990D1 (de) Bicyclische verbindung
EA200501526A1 (ru) Производные 4-замещённых хинолинов, способ и промежуточные продукты для их получения и содержащие их фармацевтические композиции
DE60309251D1 (de) Verfahren zur Herstellung von Donepezil
FI101301B1 (fi) Menetelmä terapeuttisesti käyttökelpoisten, N-substituoitujen heksahydroatsepiinijohdannaisten valmistamiseksi
EA200200611A1 (ru) Новые тетрагидропиридины, способ их получения и содержащие их фармацевтические композиции

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
AKOB Publication of a request for the grant of a patent not including a substantive examination of a patent application (a consensual patent)
PKB1 Consensual patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20110808

Year of fee payment: 10

PK10 Patent expired after termination of 10 years for consensual patent

Effective date: 20120817